Journal of Theoretical BiologySystems BiologyPeer-reviewed journal article
Drug-loaded nanoparticles for cancer therapy: a high-throughput multicellular agent-based modeling study
Yafei WangiD, John MetzcariD, Elmar BucheriD, Heber Lima da RochaiD, Vikram JadhaoiD, Randy W. HeilandiD, Hermann B. FrieboesiD, Paul MackliniD
Abstract
Interactions between biological systems and engineered nanomaterials have become an important area of study due to the application of nanomaterials in medicine. In particular, the application of nanomaterials for cancer diagnosis or treatment presents a challenging opportunity due to the complex biology of this disease spanning multiple time and spatial scales. A system-level analysis would benefit from mathematical modeling and computational simulation to explore the interactions between anticancer drug-loaded nanoparticles (NPs), cells, and tissues, and the associated parameters driving this system and a patients overall response. Although a number of models have explored these interactions in the past, few have focused on simulating individual cell-NP interactions. This study develops a multicellular agent-based model of cancer nanotherapy that simulates NP internalization, drug release within the cell cytoplasm, "inheritance" of NPs by daughter cells at cell division, cell pharmacodynamic response to the intracellular drug, and overall drug effect on tumor dynamics. A large-scale parallel computational framework is used to investigate the impact of pharmacokinetic design parameters (NP internalization rate, NP decay rate, anticancer drug release rate) and therapeutic strategies (NP doses and injection frequency) on the tumor dynamics. In particular, through the exploration of NP "inheritance" at cell division, the results indicate that cancer treatment may be improved when NPs are inherited at cell division for cytotoxic chemotherapy. Moreover, smaller dosage of cytostatic chemotherapy may also improve inhibition of tumor growth when cell division is not completely inhibited. This work suggests that slow delivery by "heritable" NPs can drive new dimensions of nanotherapy design for more sustained therapeutic response.
- Citations
- 2
- FWCI
- 1.44
- Field percentile
- top 18%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Spatial-temporal analysis of nanoparticles in live tumor spheroids impacted by cell origin and density
A. Ahmed-Cox, E. Pandzic, … M. Kavallaris·bioRxiv·Oct 26, 2021
- Beyond One-Size-Fits-All: Tumor Biology Influences Nanoparticle Behaviour in Cancer Models
M. Bravo, G. Solís-Fernandez, … Susana Rocha·bioRxiv·Mar 26, 2025
- On predicting heterogeneity in nanoparticle dosage
C. V. Dowling, P. M. Cevaal, … S. T. Johnston·bioRxiv·May 26, 2022
- Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity
S. Pieper, H. Onafuye, … K. Langer·bioRxiv·Aug 29, 2018
- Regulation of cell-nanoparticle interactions through mechanobiology
Marco Cassani, Francesco Niro, … Giancarlo Forte·Nano LettersPeer-reviewed·Jan 8, 2025
- Optimizing T-cell-mediated cancer killing: An agent-based model
Andrew P. Yu, Xingjian Zhang, Lance L. Munn·bioRxiv·Oct 21, 2025